Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2004-02-09
2008-09-23
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S143100, C424S144100
Reexamination Certificate
active
07427401
ABSTRACT:
A method of isolating a monoclonal antibody capable of inhibiting any one of IL-3, GM-CSF and IL-5 binding to the common receptor βc, or a monoclonal antibody capable of inhibiting the cytokines binding to a receptor analogous to βc. The method includes the steps of immunizing an animal with a cytokine receptor or portion of a cytokine containing the critical binding site which portion includes the extracellular domain 4 or analogous domain in the analogous common receptor or part thereof. Antibodies producing cells from the animal are then isolated and fused with a myeloma cell line and then screened for a cell line that produces an antibody of the desired type. A monoclonal antibody, or fragments thereof capable of inhibiting the binding of the cytokines IL-3, GM-CSF and IL-5 to the βcreceptor, and a hybridoma cell line producing the antibody are also claimed.
REFERENCES:
patent: WO 97/28190 (1997-08-01), None
Menzies-Gow A, Robinson DS. 2002, Curr Opin Pulm Med. vol. 8(1):33-38. Eosinophils, eosinophilic cytokines (IL-5), and anti-eosinophilic therapy in asthma.
Canhao et al. (2000) J. Rheumatol., 27(4):1102-1103.
Fox et al. (1997), Curr Opin Rheumatol, 9(5):393-399.
Molina et al. (1996), 60(6):699.
Beers and Berkow, The Merck Manual of diagnosis and therapy. 17thedition, (1999), pp. 944-955.
Bagley, C.J., et al. Blood 1997 vol. 89 (5) pp. 1471-1482.
Sun, Q. et al. Blood, 1996 vol. 88 (10) Suppl. 1 Abstract 2170 p. 545a.
Stomski et al. “Human Interleukin-3 (IL-3) Induces Disulfide-Linked IL-3 Receptor α- and β-Chain Heterodimerization, Which is Required for Receptor Activation but Not High-Affinity Binding”,Molecular and Cellular Biology, 16(6): p. 3035-3046, 1996.
Woodcock et al. The Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Receptor Exists as a Preformed and Receptor Complex That Can Be Activated by GM-CSF, Interleukin-3, or Interleukin-5′,Blood, 90(8): p. 3005-3017, 1997.
Watanabe et al. “Monoclonal Antibody Against the Common β Subunit (βc) of the Human Interleukin-3 (IL-3), IL-5, and Granulocyte-Macrophage Colony-Stimulating Factor Receptors Shows Upregulation of βcby IL-1 and Tumor Necrosis Factor-α”,Blood, 80(9): p. 2215-2220, 1992.
“Granulocyte-Macrophage Colony-Stimulating Factor Mimicry and Receptor Interactions”,Immunol. Res., 13: p. 96-109, 1994.
D'Andrea Richard
Lopez Angel
Foley & Lardner LLP
Medvet Science Pty Ltd.
Mertz Prema
LandOfFree
Method of modulating leukemic cell and eosinphil activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of modulating leukemic cell and eosinphil activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of modulating leukemic cell and eosinphil activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3975562